Ovid Therapeutics Reports Q3 Loss of $20.8 Million with GAAP EPS of -$0. ...
Clinical-Stage Biotech Pushes Three Proof-of-Concept Programs Toward 2027 Readouts with $161.4 Million in Cash Related Stocks: OVID ,
Clinical-Stage Biotech Pushes Three Proof-of-Concept Programs Toward 2027 Readouts with $161.4 Million in Cash Related Stocks: OVID ,